The company is paying China-based biotech LaNova Medicines $588 million for the kind of dual-pronged antibody drug that ...

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

A new drug strategy that regulates the tumor immune microenvironment may transform a tumor that resists immunotherapy into a ...

UCSF researchers develop customizable SNIPR sensors that activate engineered cells only near tumors, promising precise cancer ...

Clatterbridge was the first cancer research centre in the UK to give an injection of the Transgene experimental immunotherapy ...

A new study out of Harvard Medical School is opening the door for cancer patients with a rare but dangerous heart condition ...

TIL-Tregs specifically increase GLUT3 expression for glucose uptake in tumors. - GLUT3 fuels protein O-GlcNAcylation, ...

Aggressive non-Hodgkin lymphoma is typically treated with intravenous chemo-immunotherapy. "This is a cocktail of various ...

The immune system is a major target for cancer treatments. Immune checkpoint inhibitors and CAR-T cell therapy can ...

Some patients being treated with immune checkpoint inhibitors, a type of cancer immunotherapy, develop a dangerous form of heart inflammation called myocarditis. Researchers have now uncovered the ...

Dr. Watanabe and his team from Niigata University have revealed that PET/CT image analysis using artificial intelligence (AI) ...

Patient-derived organoids (PDOs) are revolutionizing cancer research, enhancing drug testing and personalized treatment ...